En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
INNOSUISSE
Numéro de projet
13240.1;10 PFLS-LS
Titre du projet
CAMEO- Characterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other diseases: a combined modelling/experimental study
Titre du projet anglais
CAMEO- ChAracterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other disEases: a combined mOdelling/experimental study

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Description succincte
-
Anzeigen
-
Anzeigen
Résumé des résultats (Abstract)
-
Anzeigen
-
Anzeigen

Textes saisis


CatégorieTexte
Description succincte
(Anglais)
CAMEO- ChAracterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other disEases: a combined mOdelling/experimental study
Description succincte
(Français)
CAMEO- Characterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other diseases: a combined modelling/experimental study
Résumé des résultats (Abstract)
(Anglais)
The aim of this project is the characterization and optimization of Toll-like receptor 7 modulators¿ structure. Computational modeling, in synergy with cellular and molecular biology will provide detailed molecular information about their self-assembly properties, their interaction with the receptors and off-target problems. This knowledge will accelerate and focus the drugs optimization process leading to the GLP IND -enabling studies for entering subsequent clinical phases
Résumé des résultats (Abstract)
(Français)
The aim of this project is the characterization and optimization of Toll-like receptor 7 modulators¿ structure. Computational modeling, in synergy with cellular and molecular biology will provide detailed molecular information about their self-assembly properties, their interaction with the receptors and off-target problems. This knowledge will accelerate and focus the drugs optimization process leading to the GLP IND -enabling studies for entering subsequent clinical phases